Published in J Biol Chem on September 19, 2002
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
Probing cellular protein complexes using single-molecule pull-down. Nature (2011) 3.92
Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A (2003) 3.75
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol (2013) 2.06
FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells. Proc Natl Acad Sci U S A (2006) 2.04
Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry (2004) 2.03
Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J Cell Biol (2011) 1.91
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89
Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer. EMBO J (2009) 1.86
MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol (2008) 1.86
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A (2012) 1.82
Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci U S A (2007) 1.81
Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci U S A (2007) 1.66
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J (2006) 1.64
BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48
A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol (2007) 1.47
Improved methodical approach for quantitative BRET analysis of G Protein Coupled Receptor dimerization. PLoS One (2014) 1.44
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem (2008) 1.34
A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A (2006) 1.33
Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J (2003) 1.30
Abundance, complexation, and trafficking of Wnt/beta-catenin signaling elements in response to Wnt3a. J Mol Signal (2007) 1.27
Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem J (2005) 1.24
The bile acid receptor TGR5 does not interact with β-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem (2013) 1.23
GPCR dimers fall apart. Sci Signal (2010) 1.17
Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem (2008) 1.17
CrossTalk opposing view: Weighing the evidence for class A GPCR dimers, the jury is still out. J Physiol (2014) 1.10
Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J (2007) 1.08
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai. J Biol Chem (2010) 1.07
Ca2+-dependent structural rearrangements within Na+-Ca2+ exchanger dimers. Proc Natl Acad Sci U S A (2011) 1.07
Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem (2011) 1.06
Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends Biotechnol (2010) 1.06
The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem (2010) 1.05
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing g protein-coupled receptor 7) splice variants from human fetal membranes. Endocrinology (2007) 1.04
Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic (2009) 1.03
Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry (2006) 1.03
Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J (2005) 1.03
Oligomeric size of the m2 muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. J Biol Chem (2010) 1.03
Constitutive dimerization of the G-protein coupled receptor, neurotensin receptor 1, reconstituted into phospholipid bilayers. Biophys J (2009) 1.02
Follice-stimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing. Endocrinology (2007) 1.02
Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol (2010) 1.02
The 'state' of beta-adrenoceptors. Br J Pharmacol (2003) 1.02
Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest (2004) 1.01
The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem (2010) 1.01
Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol Pharmacol (2013) 1.00
Bioluminescence resonance energy transfer studies reveal constitutive dimerization of the human lutropin receptor and a lack of correlation between receptor activation and the propensity for dimerization. J Biol Chem (2009) 0.99
Dimerization of ADAR2 is mediated by the double-stranded RNA binding domain. RNA (2006) 0.99
Lipid raft-mediated regulation of G-protein coupled receptor signaling by ligands which influence receptor dimerization: a computational study. PLoS One (2009) 0.98
Structural determinants underlying constitutive dimerization of unoccupied human follitropin receptors. Cell Signal (2009) 0.98
Nuclear GPCRs in cardiomyocytes: an insider's view of β-adrenergic receptor signaling. Am J Physiol Heart Circ Physiol (2011) 0.97
G protein-coupled receptors and resistance to inhibitors of cholinesterase-8A (Ric-8A) both regulate the regulator of g protein signaling 14 RGS14·Gαi1 complex in live cells. J Biol Chem (2011) 0.96
Internalization dissociates β2-adrenergic receptors. PLoS One (2011) 0.95
Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev Technol (2010) 0.95
Setting Up a Bioluminescence Resonance Energy Transfer High throughput Screening Assay to Search for Protein/Protein Interaction Inhibitors in Mammalian Cells. Front Endocrinol (Lausanne) (2012) 0.93
Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. J Biol Chem (2012) 0.93
Third-party bioluminescence resonance energy transfer indicates constitutive association of membrane proteins: application to class a g-protein-coupled receptors and g-proteins. Biophys J (2010) 0.93
Unraveling receptor stoichiometry using bret. Front Endocrinol (Lausanne) (2012) 0.92
Molecular organization and dynamics of the melatonin MT₁ receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J (2010) 0.92
Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol (2011) 0.91
Receptor heterodimerization: a new level of cross-talk. J Clin Invest (2006) 0.91
Characterization of the mode of action of a potent dengue virus capsid inhibitor. J Virol (2014) 0.91
Segregation of family A G protein-coupled receptor protomers in the plasma membrane. Mol Pharmacol (2013) 0.91
Oligomerization of G-protein-coupled receptors: lessons from the yeast Saccharomyces cerevisiae. Eukaryot Cell (2005) 0.90
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol (2013) 0.90
Multiplexing of multicolor bioluminescence resonance energy transfer. Biophys J (2010) 0.90
Mathematical models for quantitative assessment of bioluminescence resonance energy transfer: application to seven transmembrane receptors oligomerization. Front Endocrinol (Lausanne) (2012) 0.89
G Protein-Coupled Receptor Heteromers. Annu Rev Pharmacol Toxicol (2015) 0.88
Interactions and subcellular distribution of DNA replication initiation proteins in eukaryotic cells. Mol Genet Genomics (2007) 0.88
Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor. PLoS One (2011) 0.88
FRET in Membrane Biophysics: An Overview. Front Physiol (2011) 0.87
G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand? Br J Pharmacol (2011) 0.86
Bioluminescence resonance energy transfer reveals the adrenocorticotropin (ACTH)-induced conformational change of the activated ACTH receptor complex in living cells. Endocrinology (2010) 0.86
Investigation of prolactin receptor activation and blockade using time-resolved fluorescence resonance energy transfer. Front Endocrinol (Lausanne) (2011) 0.86
Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain. J Biol Chem (2008) 0.86
Spinophilin as a novel regulator of M3 muscarinic receptor-mediated insulin release in vitro and in vivo. FASEB J (2012) 0.85
BRET evidence that β2 adrenergic receptors do not oligomerize in cells. Sci Rep (2015) 0.85
Functional significance of serotonin receptor dimerization. Exp Brain Res (2013) 0.84
Varicella zoster virus ORF25 gene product: an essential hub protein linking encapsidation proteins and the nuclear egress complex. J Proteome Res (2011) 0.84
Conformational dynamics of Kir3.1/Kir3.2 channel activation via δ-opioid receptors. Mol Pharmacol (2012) 0.83
Regulation of the subcellular localization of the G-protein subunit regulator GPSM3 through direct association with 14-3-3 protein. J Biol Chem (2012) 0.83
A cell surface inactive mutant of the human lutropin receptor (hLHR) attenuates signaling of wild-type or constitutively active receptors via heterodimerization. Cell Signal (2009) 0.83
Receptor-Heteromer Investigation Technology and its application using BRET. Front Endocrinol (Lausanne) (2012) 0.82
Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression. Proc Natl Acad Sci U S A (2015) 0.82
A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. Methods Mol Biol (2013) 0.82
Biophysical Detection of Diversity and Bias in GPCR Function. Front Endocrinol (Lausanne) (2014) 0.82
Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation. FASEB J (2015) 0.82
Fluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling. Mol Cell Endocrinol (2010) 0.81
Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. Pharmacol Res (2013) 0.81
Revisiting and questioning functional rescue between dimerized LH receptor mutants. Mol Endocrinol (2012) 0.81
Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation. J Biol Chem (2013) 0.81
Protein-protein interactions at the adrenergic receptors. Curr Drug Targets (2012) 0.81
Modelling the interdependence between the stoichiometry of receptor oligomerization and ligand binding for a coexisting dimer/tetramer receptor system. Br J Pharmacol (2009) 0.81
Single molecule analysis of functionally asymmetric G protein-coupled receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. J Biol Chem (2014) 0.80
Analysis of RXR/THR and RXR/PPARG2 heterodimerization by bioluminescence resonance energy transfer (BRET). PLoS One (2013) 0.80
Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A (2003) 3.75
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol (2002) 3.45
Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33
Real-time monitoring of receptor and G-protein interactions in living cells. Nat Methods (2005) 2.72
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci (2005) 2.63
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol (2006) 2.62
The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci (2007) 2.46
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Real-time monitoring of ubiquitination in living cells by BRET. Nat Methods (2004) 2.23
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol (2005) 2.14
Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J (2002) 2.13
Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem (2005) 2.10
Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem (2010) 2.06
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J Biol Chem (2004) 2.03
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nat Cell Biol (2003) 1.96
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J (2005) 1.90
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Restructuring G-protein- coupled receptor activation. Cell (2012) 1.83
Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol (2002) 1.76
Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J (2008) 1.71
Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem (2002) 1.68
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen (2005) 1.61
Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem (2002) 1.59
Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol (2008) 1.56
Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol Ther (2003) 1.55
Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J (2004) 1.55
BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48
Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells. J Cell Sci (2006) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol (2004) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem (2003) 1.44
Homo- and hetero-oligomerization of beta-arrestins in living cells. J Biol Chem (2005) 1.39
Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem (2004) 1.39
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A (2004) 1.38
Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol Cell Biol (2006) 1.38
Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem (2008) 1.34
Experimental challenge to a 'rigorous' BRET analysis of GPCR oligomerization. Nat Methods (2007) 1.32
Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J (2003) 1.30
Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol (2009) 1.30
Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol (2008) 1.29
Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord (2004) 1.27
Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET). Curr Protoc Neurosci (2006) 1.26
G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem (2002) 1.23
Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J Biol Chem (2007) 1.19
Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem (2011) 1.19
Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol (2013) 1.19
Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem (2008) 1.17
The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J Recept Signal Transduct Res (2002) 1.17
Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res (2005) 1.17
Resonance energy transfer approaches in molecular pharmacology and beyond. Trends Pharmacol Sci (2007) 1.16
Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between beta-arrestins and AP-2. J Biol Chem (2007) 1.15
An evolutionarily conserved autoinhibitory molecular switch in ELMO proteins regulates Rac signaling. Curr Biol (2010) 1.15
Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. Neuropsychopharmacology (2008) 1.14
Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations. Addict Biol (2012) 1.13
Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem (2004) 1.12
Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human delta opioid receptor. J Biol Chem (2006) 1.11
Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation. J Biol Chem (2003) 1.10
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J (2007) 1.08
Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal (2012) 1.07
Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles. Biochemistry (2007) 1.07
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai. J Biol Chem (2010) 1.07
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor. J Biol Chem (2010) 1.06
The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal (2006) 1.06
Multimerization of Staufen1 in live cells. RNA (2010) 1.05
Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A (2011) 1.05
Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol (2011) 1.05
A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods (2005) 1.04
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun (2013) 1.04
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol (2004) 1.04
Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic (2009) 1.03
Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J (2005) 1.03
Oligomeric size of the m2 muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. J Biol Chem (2010) 1.03
Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One (2012) 1.02
Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony. J Neurosci (2010) 1.02
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther (2009) 1.01
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A (2013) 1.00
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol (2010) 1.00
A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J Biol Chem (2004) 1.00